Kawamura N, Okada K, Tanaka N, Kumamoto Y, Kishi H, Niijima T, Goto H, Machida T, Suzuki K, Naide Y
Jpn J Antibiot. 1986 Nov;39(11):2945-58.
Intravenous drip infusion of a new aminoglycoside agent, astromicin (ASTM), was used for various urological infections, and its clinical efficacy and safety were studied. Each of almost all the patients tested was given 200 mg of ASTM twice a day by intravenous drip infusion. Among 114 cases with complicated urinary tract infections (UTI) evaluated according to the criteria for evaluation of drug efficacy in UTI, clinical response was excellent in 16, moderate in 54 and poor in 44. The efficacy rate was 61.4%. Among 137 cases who were evaluated for side effects, headache was observed in 1 case (0.7%), which recovered spontaneously the day after the withdrawal of the drug. Slight elevation in S-GOT, S-GPT, Al-P and others was observed in 12 cases (8.8%) as abnormal laboratory test values.
采用静脉滴注新型氨基糖苷类药物阿司米星（ASTM）治疗各种泌尿系统感染，并对其临床疗效和安全性进行研究。几乎所有受试患者均通过静脉滴注每天两次给予200mg ASTM。按照泌尿系统感染药物疗效评价标准评估的114例复杂性尿路感染（UTI）患者中，临床反应优者16例，中者54例，差者44例。有效率为61.4%。在137例接受副作用评估的患者中，1例（0.7%）出现头痛，停药后次日自行恢复。12例（8.8%）实验室检查值异常，出现谷草转氨酶、谷丙转氨酶、碱性磷酸酶等轻度升高。
